Market revenue in 2023 | USD 294.7 million |
Market revenue in 2030 | USD 468.0 million |
Growth rate | 6.8% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 58.13% in 2023. Horizon Databook has segmented the Australia inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
In July 2021, Xeljanz was made available in the Pharmaceutical Benefits Scheme to enhance the treatment availability to Australian IBD patients. This step was taken to provide care for the increasing burden of patients that required innovative medications.
This further depicts the government’s support for innovative drugs with high efficacy. In January 2022, Australia announced starting of a 4-year partnership for research between Hudson Institute and Biome Bank on microbiome medicine for inflammatory bowel disease patient treatment.
The research further aims to target pediatric patients in the country for reducing the disease burden. The unmet need for access to specialists is a major factor influencing the rising IBD prevalence in the country. The development of programs to increase access to gastroenterologists is projected to propel drug adoption.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Australia inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account